Ipratrop Duo (CFC Free) Inhaler is a combination bronchodilator containing Levosalbutamol 50 mcg and Ipratropium 20 mcg per actuation, formulated for the management of chronic obstructive pulmonary disease (COPD) and asthma. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides rapid bronchodilation by relaxing airway smooth muscle, thereby improving airflow and reducing bronchospasm. Ipratropium, an anticholinergic agent, inhibits muscarinic receptors in the airway, leading to prolonged bronchodilation through decreased vagally mediated bronchoconstriction. The synergistic action of these two agents results in enhanced bronchodilation compared to monotherapy, improving respiratory function and symptom control. The inhaler is CFC-free, aligning with environmental safety standards. Ipratrop Duo is indicated for patients requiring maintenance treatment for reversible airway obstruction and is particularly beneficial in patients inadequately controlled on single bronchodilator therapy. The recommended dosage and administration should be individualized based on clinical response, with inhalation technique optimized to ensure effective drug delivery. Common adverse effects may include dry mouth, headache, tremor, and palpitations; however, the combination is generally well tolerated. Caution is advised in patients with cardiovascular disorders or hypersensitivity to any component. Regular monitoring of lung function and symptom control is recommended during therapy.